What is the typical mammography interval for average-risk women?

Prepare for the USPSTF Guidelines Test with comprehensive flashcards and multiple choice questions, each question includes hints and explanations. Get ready for your exam with confidence!

Multiple Choice

What is the typical mammography interval for average-risk women?

Explanation:
Screening interval is chosen to balance the benefits of catching cancer early with the harms of screening, such as false positives and unnecessary procedures. For average‑risk women, the guideline-supported approach is to screen every two years, especially for those aged 50 to 74, where the overall benefit is greatest and the tradeoffs are more favorable. For women aged 40–49, starting screening before 50 is an individual decision that takes patient values and risk factors into account, rather than a universal mandate. After age 75, screening should also be individualized based on overall health and preferences. So the option that describes biennial screening for 50–74 with consideration for starting earlier in 40–49 depending on policy or individualized discussion aligns with the evidence. Choices proposing annual screening starting at 30, or screening every 3 years after 60, or screening only when symptomatic, do not fit the typical guideline approach.

Screening interval is chosen to balance the benefits of catching cancer early with the harms of screening, such as false positives and unnecessary procedures. For average‑risk women, the guideline-supported approach is to screen every two years, especially for those aged 50 to 74, where the overall benefit is greatest and the tradeoffs are more favorable. For women aged 40–49, starting screening before 50 is an individual decision that takes patient values and risk factors into account, rather than a universal mandate. After age 75, screening should also be individualized based on overall health and preferences. So the option that describes biennial screening for 50–74 with consideration for starting earlier in 40–49 depending on policy or individualized discussion aligns with the evidence. Choices proposing annual screening starting at 30, or screening every 3 years after 60, or screening only when symptomatic, do not fit the typical guideline approach.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy